Montanova Capital LLC Trims Holdings in Fulcrum Therapeutics, Inc. $FULC

Montanova Capital LLC trimmed its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 43.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,680,921 shares of the company's stock after selling 2,880,190 shares during the quarter. Montanova Capital LLC owned about 4.82% of Fulcrum Therapeutics worth $13,472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Quarry LP purchased a new stake in Fulcrum Therapeutics in the third quarter worth about $35,000. Meeder Asset Management Inc. purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $39,000. Summit Securities Group LLC purchased a new position in shares of Fulcrum Therapeutics during the first quarter valued at approximately $53,000. The Manufacturers Life Insurance Company bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter worth approximately $61,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock worth $64,000 after buying an additional 9,092 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Up 1.0%

Shares of FULC opened at $3.89 on Tuesday. The company has a market capitalization of $296.81 million, a P/E ratio of -3.21 and a beta of 3.05. The firm has a 50 day moving average of $3.73 and a 200 day moving average of $5.93. Fulcrum Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.69 EPS for the current year.

Analysts Set New Price Targets

FULC has been the subject of a number of analyst reports. Piper Sandler lowered Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded Fulcrum Therapeutics from an "overweight" rating to an "underweight" rating in a report on Wednesday, June 3rd. Leerink Partners downgraded Fulcrum Therapeutics from an "outperform" rating to a "market perform" rating and set a $4.00 price target for the company. in a report on Tuesday, June 2nd. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 2nd. Finally, Stifel Nicolaus lowered Fulcrum Therapeutics from a "buy" rating to a "hold" rating and set a $3.00 price target for the company. in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average target price of $8.20.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the company's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the transaction, the director directly owned 10,927 shares of the company's stock, valued at $39,883.55. This represents a 62.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.30% of the stock is owned by corporate insiders.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source